Bristol Myers Squibb Third Quarter 2026 Earnings - BRISTOL MYERS SQUIBB CO

Explicit Guidance:

• 2026 Non-GAAP EPS: Raised to a range of $6.35–$6.55 (excluding the $0.58/share impact from acquired and in-process R&D charges and licensing income; the midpoint increased by ~15 cents/share).
• 2026 Revenue: Upward revision implied by strong Q3 performance and full-year outlook, though specific total revenue numbers are not restated in the provided text.
• Legacy Portfolio Revenue: Now expected to decline 3%–5% for the full year 2026.
• Eliquis Revenue: Full-year 2026 growth expected to remain 20%–25%.
• Financial Margins: Maintaining prior guidance for Gross Margin (68.4% in Q3), Operating Expenses, and Effective Tax Rate (14.1% in Q3).
• Other Income/Expense: Slightly lowering expense level on this line.
• Strategic Productivity: Targeting $2 billion in efficiency savings to be achieved by the end of 2027.
• 2027 Financial Outlook: Anticipating a revenue step-down of $1.5–$2 billion in 2027 primarily driven by the U.S. LOE (Loss of Exclusivity) impact.

Business-Segment Outlook:

• Growth Portfolio: Expected to sustain double-digit growth; now includes eight medicines annualizing over $1 billion based on Q3 sales.
• Eliquis (Cardiovascular/Immunology): Facing U.S. growth offset by European LOE in Q4 2026; anticipated $1.5–$2 billion revenue decline in 2027 due to European patent expiration.
• Opdivo/Oncology: Revenue declining (-6% in Q3) due to conversion to Cuvantic.
• Cuvantic: On a strong trajectory; annualizing over $1.3 billion (Q3 revenue $334M, sequential growth 28%); target conversion of 30%–40% of Opdivo IV business to subcutaneous Cuvantic by end of launch phase (currently ~17% converted).
• Chemzios: Continued strong demand; inventory drawdown in Q3 expected to normalize in Q4 2026; expanded indication approved for pediatric obstructive HCM.
• Reblozyl: 22% growth (Q3 revenue $750M) driven by first-line MDS-associated anemia uptake.
• Breonzi: 48% growth (Q3 revenue $526M) driven by U.S. and international demand.
• ZemBexis (Cell Mod): First approved cell mod; launched for multiple myeloma with positive early feedback; majority of use expected from community settings (70–80%); anticipated to become a foundational therapy alongside Mezignamide.
• Mezignamide: Second cell mod; PDUFA date May 13, 2027; potential to serve different multiple myeloma segment.
• Admilpirant (IPF/PPF): Phase 3 results for IPF met primary endpoint (60mg dose) in Q3; Phase 3 results for Progressive Pulmonary Fibrosis (PPF) expected in Q1 2027; market opportunity expected to nearly double (current ~$4B) with a large second-line switch/add-on market.
• Milvexian: Phase 3 data for Secondary Stroke Prevention (SSP) expected before year-end 2026; Phase 3 data for Atrial Fibrillation expected Q1 2027.
• ZolaCell (Autoimmune): Program paused for review; safety signal identified as a reagent activation issue (resolved); awaiting regulatory discussions to restart; treating severe autoimmune disorders.
• Arlocell (CAR-T): Positive registrational Phase II data in post-BCMA multiple myeloma; potential to set new standard of care.
• RAISE-101 (Radiopharmaceutical): Positive interim PFS data in GEPNETs; engaging with FDA for next steps; launch expected to follow as the first radiopharmaceutical product.
• Neuroscience (CoBenfi): Launching Alzheimer's Disease Psychosis (ADP) indications following schizophrenia data; expecting continued growth in schizophrenia; facing challenges with patient titration to effective dose (125mg) and nausea management; ADP market estimated at 7 million patients in the U.S. with no approved treatments.
• SOTIC2 (Lupus): Phase 3 readouts expected before year-end 2026.
• SOTIC2 (Psoriatic Arthritis): Supporting recent indication in adults.
• Glucotamide: Advancing in lymphoma; first Phase 2 data in frontline follicular lymphoma to be presented at ASH; registrational data in high-risk first-line LBCL expected in 2027.

Market and Competitive Outlook:

• Multiple Myeloma: Shift toward cell mods and CAR-T (Arlocell, ZemBexis, Mezignamide); focus on replacing Revlimid/lenalidomide-based regimens.
• IPF/PPF Market: Expected to double as older therapies are replaced by disease-modifying options (Admilpirant); significant need for well-tolerated treatments with better safety profiles.
• Small Cell Lung Cancer (SCLC): Welcoming competitor data (e.g., MDeltra) to benchmark novel mechanisms; strategy focuses on combination therapies and subtyping patients for subsequent lines of therapy.
• Radiopharmaceuticals: RAISE-101 expected to establish standard of care after Lutathera in GEPNETs; estimated 18,000 annual diagnoses in the U.S., with ~70% requiring subsequent therapy post-Lutathera.
• Oncology Pipeline: Expecting multiple INDs from the RAISE Bio platform over the next five years; pipeline includes liver cancer (GPC3) and prostate cancer (SCP3).
• Neuroscience (CoBenfi): Differentiation in ADP through lack of black box warnings and suitability for long-term care facilities; education on managing nausea expected to drive adoption.

Macro / Industry Outlook:

• Sales Growth Rates: Discussed on an underlying basis, excluding foreign exchange impacts.
• Pricing: Eloquis growth driven partly by net price increases; no specific macro rate or FX guidance provided beyond exclusion from growth metrics.
• Regulatory Environment: Active engagement with FDA on RAISE-101 and Admilpirant; emphasis on regulatory submission readiness for multiple assets.

Strategic Initiatives:

• Manufacturing Expansion (Houston): Announced $2.3 billion investment for a new manufacturing campus at Generation Park; will create ~500 skilled jobs; capable of small molecules, biologics, and ADCs.
• Manufacturing Expansion (Indiana): Ray's Bio investing >$170 million for a radiopharmaceutical facility; creating up to 100 new jobs by end of 2029.
• R&D Efficiency: "Rewiring" operations to be faster and more efficient; strategic productivity initiative targeting $2 billion savings by end of 2027.
• AI Integration: Embedding AI across R&D value chain (discovery to commercialization); targeting 20–30% reduction in drug testing timelines and cutting in half the time from target selection to lead molecule identification; partnerships with Anthropic and NVIDIA active.
• Capital Allocation: Maintaining balanced approach; prioritizing business development (M&A, partnerships, licensing) in core therapeutic areas; maintaining dividend; $13 billion cash equivalents and marketable securities as of Sept 30, 2026.
• M&A/Business Development: "North Star" is sustained growth into the next decade; agnostic on deal size; focus on strategic fit, scientific strength, and financial sense; actively evaluating opportunities.

Risks and Headwinds to Outlook:

• LOE Impact: Eliquis revenue decline of $1.5–$2 billion expected in 2027 due to patent expiration.
• ZolaCell Safety: Recent fatal case (sepsis/pneumonia) in autoimmune CAR-T trial; program paused pending review and regulatory restart approval.
• Admilpirant Dosing: Mixed results at 120mg dose in IPF study; need to confirm efficacy in PPF; final regulatory approval contingent on outcome.
• Inventory Dynamics: Chemzios Q3 revenue impacted by inventory drawdown (expected to normalize in Q4); CoBenfi Q3 impacted by destocking following Q2 build.
• Pipeline Timing: Dependence on specific readout success (e.g., Milvexian SSP/AFib, SOTIC2 lupus) to drive future valuation and guidance.
• Competitive Landscape: Ongoing competition in oncology (e.g., Opdivo conversion, SCLC data) and emerging therapies in IPF/PPF.

Management Tone on the Future:

• Confidence: High confidence in the "next wave" of launches and pipeline progression; described as "energized and focused."
• Strategic Flexibility: Emphasis on "strategic flexibility" to invest in growth, pursue BD, and return cash to shareholders.
• Long-term View: Focus on "sustained growth" into the next decade; belief in the ability to manage LOE cycles and pipeline transitions.
• Discipline: Repeated emphasis on financial discipline, cost structure alignment, and rigorous clinical trial scrutiny.
• Hedges: Explicitly notes forward-looking statements are estimates as of the call date and may differ materially from actual results; advises not to rely on estimates as of future dates.

Miscellaneous:

• Key Personnel: Chris Berner (CEO), David Elkins (CFO), Adam Lienkowski (CCO), Christian Massachese (CMO).
• Data Presentation: PFS data for ZemBexis to be presented at ASH in December; IPF/PPF data to be presented at medical meetings in 2027; ADEPT program data at CTAD in November.
• Financial Adjustments: Earnings per share guidance excludes $0.58/share impact from acquired and in-process R&D charges.
• Guidance Updates: Full-year guidance raised based on YTD performance and full-year outlook; 2026 guidance reflects a legacy portfolio decline and strong growth portfolio performance.